共 50 条
Psoriasis management tree based on comorbidity
被引:0
|作者:
Amara, Shivkar
[1
]
Pasumarthi, Anusha
[1
]
Parikh, Neil
[2
]
Kodali, Nilesh
[3
]
Lebwohl, Mark
[1
]
Monks, George
[4
]
机构:
[1] Icahn Sch Med Mt Sinai, Kimberly & Eric J Waldman Dept Dermatol, New York, NY 10029 USA
[2] Boston Univ, Chobanian & Avedisian Sch Med, Boston, MA USA
[3] Rugters New Jersey Med Sch, Newark, NJ USA
[4] Univ Oklahoma, Coll Med, Dept Dermatol, Oklahoma City, OK USA
关键词:
psoriasis;
psoriatic arthritis;
biological agents;
therapies;
comorbidities;
LONG-TERM SAFETY;
ACTIVE CROHNS-DISEASE;
NECROSIS-FACTOR-ALPHA;
INFLAMMATORY-BOWEL-DISEASE;
SEVERE PLAQUE PSORIASIS;
QUALITY-OF-LIFE;
DOUBLE-BLIND;
CERTOLIZUMAB PEGOL;
PHASE-III;
MAINTENANCE THERAPY;
D O I:
10.1111/ijd.17497
中图分类号:
R75 [皮肤病学与性病学];
学科分类号:
100206 ;
摘要:
Psoriasis, a common chronic inflammatory skin disorder, encompasses various subtypes, including guttate, pustular, erythrodermic, and the most common type, plaque psoriasis. Irrespective of the subtype, psoriasis can manifest with multisystemic presentations, including psoriatic arthritis, metabolic disorders, cardiovascular disease, malignancies, chronic kidney disease (CKD), psychiatric illness, and inflammatory bowel disease (IBD). Many comorbidities and concomitant conditions must be considered when selecting the most appropriate therapy for a patient (Kaushik et al., 2019 and Monks et al., 2021) . Ongoing clinical trials and the development of new therapeutic targets contribute to the continuous improvement of available treatment options. Given the dynamic landscape of therapies, particularly when managing complex patients with multiple comorbidities, dermatologists are constantly challenged with the task of adeptly tailoring treatments to each psoriasis patient. This article systematically reviews the current evidence, presenting it as an updated Psoriasis Decision Tree to assist physicians in selecting tailored treatment options.
引用
收藏
页数:17
相关论文